P0035
Penciclovir
別名:
2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6H-purin-6-one, BRL-39123
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C10H15N5O3
CAS番号:
分子量:
253.26
NACRES:
NA.76
PubChem Substance ID:
UNSPSC Code:
51102829
MDL number:
InChI key
JNTOCHDNEULJHD-UHFFFAOYSA-N
SMILES string
NC1=NC(=O)c2ncn(CCC(CO)CO)c2N1
InChI
1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
form
powder
solubility
0.02 M potassium phosphate: soluble 2 mg/mL
antibiotic activity spectrum
viruses
mode of action
DNA synthesis | interferes, enzyme | inhibits
Quality Level
類似した製品をお探しですか？ 訪問 製品比較ガイド
Biochem/physiol Actions
Penciclovir is converted to its active form, penciclovir triphosphate, by cellular kinases. It inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. It inhibits DNA synthesis of virus-infected cells. Penciclovir has in vitro activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). It does not inhibit DNA synthesis in non-infected cells. Mode of resistance is via qualitative changes in viral thymidine kinase or DNA polymerase.
Other Notes
Keep container tightly closed in a dry and well-ventilated place.
Application
Penciclovir is a selective antiherpesvirus agent, particularly against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and varicella-zoster virus (VZV).
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
P0035-BULK: + P0035-100MG: + P0035-VAR:
jan
Weiwei Zhu et al.
International journal of pharmaceutics, 378(1-2), 152-158 (2009-05-26)
The purpose of this study was to investigate microemulsion-based hydrogel (MBH) as a topical delivery system for penciclovir. Topical delivery of penciclovir in the forms of microemulsion, MBH and the commercial cream was evaluated in vitro and in vivo. The
Qingzhi Lv et al.
International journal of pharmaceutics, 372(1-2), 191-198 (2009-05-12)
The objective of this investigation was to develop solid lipid nanoparticles (SLNs) of penciclovir and evaluate the potential of SLNs as the carrier of penciclovir for topical delivery. Penciclovir-loaded SLNs were prepared by a double (W/O/W) emulsion technique. The SLNs
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.
Teresa H Bacon et al.
Clinical microbiology reviews, 16(1), 114-128 (2003-01-15)
Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections. In spite of the distribution of over 2.3 x 10(6) kg of these nucleoside analogues, the prevalence of acyclovir resistance
A Fontanellas et al.
Gene therapy, 16(1), 136-141 (2008-08-01)
Non-invasive in vivo imaging of transgene expression is currently providing very important means to optimize gene therapy regimes. Results in non-human primates are considered the most predictive models for the outcome in patients. In this study, we have documented that
Jocelyne Piret et al.
Antimicrobial agents and chemotherapy, 55(2), 459-472 (2010-11-17)
Herpes simplex viruses (HSV) type 1 and type 2 are responsible for recurrent orolabial and genital infections. The standard therapy for the management of HSV infections includes acyclovir (ACV) and penciclovir (PCV) with their respective prodrugs valacyclovir and famciclovir. These
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）